These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 6232241)

  • 1. The effect of experimental conditions on the assessment of T cell immunomodulation by biological response modifiers (thymosin fraction five).
    Talmadge JE; Benedict KL; Uithoven KA; Lenz BF
    Immunopharmacology; 1984 Feb; 7(1):17-26. PubMed ID: 6232241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunomodulation and therapeutic characterization of thymosin fraction five.
    Talmadge JE; Uithoven KA; Lenz BF; Chirigos M
    Cancer Immunol Immunother; 1984; 18(3):185-94. PubMed ID: 6239686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of murine thymocyte cytotoxic T cell responses by thymosin.
    Zatz MM; Goldstein AL
    Immunopharmacology; 1983 Jun; 6(1):65-74. PubMed ID: 6603447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thymosin: immunomodulatory and therapeutic characteristics.
    Talmadge JE
    Prog Clin Biol Res; 1984; 161():457-65. PubMed ID: 6237369
    [No Abstract]   [Full Text] [Related]  

  • 5. The biological effect of three thymosin fraction 5 polypeptides in the murine mixed lymphocyte reaction.
    Baxevanis CN; Perez S; Kokkinopoulos D; Papamichail M
    Immunology; 1985 Apr; 54(4):723-30. PubMed ID: 3156810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thymosin modulation of suppressor function in mice and man.
    Serrou B; Rosenfeld C; Caraux J; Thierry C; Cupissol D; Goldstein A
    Ann N Y Acad Sci; 1979; 332():95-100. PubMed ID: 161154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunomodulation by an adenylate cyclase activator, NKH477, in vivo and vitro.
    Furukawa Y; Matsumori A; Hirozane T; Matsui S; Sato Y; Ono K; Sasayama S
    Clin Immunol Immunopathol; 1996 Apr; 79(1):25-35. PubMed ID: 8612348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Augmentation of cytotoxic responses by prostaglandin E2.
    Häcker-Shahin B; Dröge W
    Cell Immunol; 1985 Mar; 91(1):43-51. PubMed ID: 3871666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of action of thymosin. I. Thymosin fraction 5 increases lymphokine production by mature murine T cells responding in a mixed lymphocyte reaction.
    Zatz MM; Goldstein AL
    J Immunol; 1985 Feb; 134(2):1032-8. PubMed ID: 3155533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Capacity of different cell types to stimulate cytotoxic T lymphocyte precursor cells in the presence of interleukin 2.
    Dröge W; Moyers C; Wehrmaker A; Schmidt H; Panknin S; Männel D; Falk W
    J Immunol; 1984 Jun; 132(6):2749-59. PubMed ID: 6233360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunological reconstitution of T-cell-deprived mice. I. Inability of thymosin to restore spleen cell mitogen and tumor allograft response.
    Primus FJ; De Martino L; MacDonald R; Hansen HJ
    Cell Immunol; 1978 Jan; 35(1):25-33. PubMed ID: 145898
    [No Abstract]   [Full Text] [Related]  

  • 12. Suppressive effect of thymosin fraction 5 on proliferation of cultured human T lymphocytes.
    Wolf RE; Maca RD
    Immunopharmacology; 1986 Dec; 12(3):233-40. PubMed ID: 3493229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction and characterization of minor histocompatibility antigens. Specific primary cytotoxic T lymphocyte responses in vitro.
    Ando K; Nakashima I; Nagase F; Isobe K; Kawashima K; Hasegawa Y; Yoshida T; Iwamoto T; Hasegawa T; Muro Y
    J Immunol; 1988 Feb; 140(3):723-9. PubMed ID: 2448374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thymosin alpha1 accelerates restoration of T cell-mediated neutralizing antibody response in immunocompromised hosts.
    Li CL; Zhang T; Saibara T; Nemoto Y; Ono M; Akisawa N; Iwasaki S; Maeda T; Onishi S
    Int Immunopharmacol; 2002 Jan; 2(1):39-46. PubMed ID: 11789668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Thymosin fraction 5. Preclinical study].
    Panajotovová V; Lastovicka J; Sůla K; Nouza K; Pokorná D; Grimová J
    Cas Lek Cesk; 1989 Dec; 128(51):1615-20. PubMed ID: 2632000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoregulatory effects of fraction 5 thymus peptides. I. Thymosin alpha 1 enhances while thymosin beta 4 suppresses the human autologous and allogeneic mixed lymphocyte reaction.
    Baxevanis CN; Reclos GJ; Perez S; Kokkinopoulos D; Papamichail M
    Immunopharmacology; 1987 Apr; 13(2):133-41. PubMed ID: 2954929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis of deacetyl-thymosin beta 7 and examination of its immunological effect on the blastogenic response of T-lymphocytes of a uremic patient with cell-mediated immunodeficiency.
    Abiko T; Sekino H
    Chem Pharm Bull (Tokyo); 1988 Feb; 36(2):700-7. PubMed ID: 3261642
    [No Abstract]   [Full Text] [Related]  

  • 18. Expression of heat-stable antigen on tumor cells provides co-stimulation for tumor-specific T cell proliferation and cytotoxicity in mice.
    Wang YC; Zhu L; McHugh R; Sell KW; Selvaraj P
    Eur J Immunol; 1995 May; 25(5):1163-7. PubMed ID: 7774619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of thymosin alpha 1 on the antitumor activity of tumor-associated macrophage-derived dendritic cells.
    Shrivastava P; Singh SM; Singh N
    J Biomed Sci; 2004; 11(5):623-30. PubMed ID: 15316138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thymosin alpha 1 potentiates interleukin 2-induced cytotoxic activity in mice.
    Mastino A; Favalli C; Grelli S; Innocenti F; Garaci E
    Cell Immunol; 1991 Mar; 133(1):196-205. PubMed ID: 1991327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.